We are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE ® ”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships University of Minnesota: investigator-initiated clinical trial agreement (Apr 3, 2026; UMN sponsors IND 169118 Phase 1a/1b). B7-H3-specific patent license (5% royalty)
Indications
B7-H3+ solid tumors (basket)(Phase 1)
Status note IND filed Oct 2023; FDA cleared early Jan 2026; first patient dosed May 2026. Initial trial is a basket trial in B7-H3+ solid tumors.
GTB-3550
Stage not disclosed · ActiveModality: tri-specific killer engager (TriKE; scFv-based)
Target CD33
Indications
AML and MDS(Stage not disclosed)
Status note First-generation CD33 TriKE; positive interim clinical data (reduced CD33+ bone marrow blasts) but development paused in favor of sole development of GTB-3650.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.